{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Novelix Pharmaceuticals Ltd
Novelix Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness
Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting a changing investor sentiment amid mixed market signals. Despite a recent 4.01% dip in its share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more attractive entry point compared to its historical highs and peer group averages.
Novelix Pharmaceuticals Ltd is Rated Hold
Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Novelix Pharmaceuticals Ltd is Rated Hold
Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Novelix Pharmaceuticals Drops 8.23%: 4 Key Factors Driving the Weekly Decline
Novelix Pharmaceuticals Ltd experienced a sharp reversal this week, closing at Rs.75.82 on 19 June 2026, down 8.23% from the previous Friday’s close of Rs.82.62. This decline contrasted with the Sensex’s 2.35% gain over the same period, marking a week of significant volatility and profit-taking after the stock’s recent record highs. Despite early strength and new 52-week and all-time highs on 15 and 16 June, the stock faced sustained selling pressure in the latter half of the week, reflecting a shift in market sentiment.
Broad-Based Technical Strength Lifts Novelix Pharmaceuticals Ltd to 52-Week High of Rs 92
Surging past its previous peaks, Novelix Pharmaceuticals Ltd touched a fresh 52-week high of Rs 92 on 16 Jun 2026, marking a remarkable rally that has seen the stock gain nearly 197% over the past year, vastly outperforming the Sensex’s decline of 6.37% during the same period.
From Streak to Summit: Novelix Pharmaceuticals Ltd Hits All-Time High at Rs 92
Novelix Pharmaceuticals Ltd, a micro-cap player in the retailing sector, achieved a significant milestone on 16 Jun 2026 as its stock price touched an all-time high of Rs.92. This marks a remarkable phase in the company’s market journey, reflecting sustained gains and strong performance metrics over multiple time horizons.
Broad-Based Technical Strength Lifts Novelix Pharmaceuticals Ltd to 52-Week High of Rs 87.9
Surging to an all-time high of Rs 87.9 on 15 Jun 2026, Novelix Pharmaceuticals Ltd has demonstrated remarkable price momentum, extending gains for nine consecutive sessions and delivering a 63.28% return over this period. This rally unfolds amid a broadly positive market backdrop, with the Sensex trading near its recent peaks.
Strong Momentum Meets Stretched Valuations as Novelix Pharmaceuticals Ltd Reaches All-Time High
Novelix Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs.87.90 on 15 Jun 2026, marking a remarkable phase in the company’s stock performance within the retailing sector.
Novelix Pharmaceuticals Ltd Gains 26.14%: 6 Key Factors Driving the Surge
Novelix Pharmaceuticals Ltd delivered a remarkable weekly gain of 26.14%, closing at Rs.82.62 on 12 June 2026, significantly outperforming the Sensex’s modest 0.57% rise. The stock’s strong momentum was marked by multiple new 52-week and all-time highs, sustained buying interest, and an upgraded Mojo rating, underscoring a robust performance amid a cautious broader market environment.